Top

Published in:

01-04-2014 | Review

The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis

Authors: Yanlong Yang, Lei Xian

Published in: Tumor Biology | Issue 4/2014

Abstract

The relationship between the ERCC1/2 single nucleotide polymorphisms (SNPs) and the clinical outcomes of the platinum-based chemotherapy in the non-small cell lung cancer (NSCLC) is still inconsistent and inconclusive despite extensive investigations have been conducted to address this question. In this meta-analysis, we aim to further explore the prognostic value of the ERCC1/2 SNPs in NSCLC by analyzing all currently available evidences. Relevant studies were searched in PubMed, Embase, and China National Knowledge Infrastructure. The inclusion criteria were platinum-based chemotherapy in NSCLC patients and evaluation of clinical outcomes in relation to the ERCC1 C118T, ERCC1 C8092A, ERCC2 Asp312Asn, and ERCC2 Lys751Gln. Clinical outcomes analyzed in this study included the overall response rate, overall survival (OS), and progression-free survival (PFS). Odds ratio (OR) or hazard ratio (HR) with 95 % confidence interval (CI) were calculated to examine the risk or hazard associated with each SNP. A total of 46 studies including 9,407 NSCLC patients were qualified for this meta-analysis. For ERCC1 C118T, the T allele was associated with a poor OS (HR = 1.35, 95 % CI = 1.04–1.75); for ERCC2 Asp312Asn, the Asn variant was linked to an unfavorable OS (HR = 2.07, 95 % CI = 1.11–3.88); and for ERCC2 Lys751Gln, patients with the Gln variant have a worse OS (HR = 1.22, 95 % CI = 1.05–1.41) and PFS (HR = 1.35, 95 % CI = 1.07–1.71). In addition, the main findings of the ERCC1/2 SNPs on chemotherapy toxicity were also summarized. This meta-analysis suggested that the ERCC1 C118T, ERCC2 Asp312Asn, and Lys751Gln may be useful biomarkers to predict the clinical outcomes of the platinum-based chemotherapy in NSCLC patients.

Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300. doi:10.3322/caac.20073.PubMedCrossRef

Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367–80. doi:10.1056/NEJMra0802714.PubMedCrossRef

Wright G, Manser RL, Byrnes G, Hart D, Campbell DA. Surgery for non-small cell lung cancer: systematic review and meta-analysis of randomised controlled trials. Thorax. 2006;61(7):597–603. doi:10.1136/thx.2005.051995.PubMedCentralPubMedCrossRef

Custodio AB, Gonzalez-Larriba JL, Bobokova J, Calles A, Alvarez R, Cuadrado E, et al. Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2009;4(7):891–910. doi:10.1097/JTO.0b013e3181a4b8fb.

Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res. 2002;62(17):4899–902.PubMed

van de Vaart PJ, Belderbos J, de Jong D, Sneeuw KC, Majoor D, Bartelink H, et al. DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer J Int Cancer. 2000;89(2):160–6.CrossRef

Li F, Sun X, Sun N, Qin S, Cheng H, Feng J, et al. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Am J Clin Oncol. 2010;33(5):489–94. doi:10.1097/COC.0b013e3181b9cedc.PubMedCrossRef

Yin Z, Zhou B, He Q, Li M, Guan P, Li X, et al. Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma. BMC cancer. 2009;9:439. doi:10.1186/1471-2407-9-439.PubMedCentralPubMedCrossRef

Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207–14.PubMedCrossRef

10.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–16.PubMedCrossRef

11.

Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. doi:10.1186/1745-6215-8-16.PubMedCentralPubMedCrossRef

12.

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clin Res). 2003;327(7414):557–60. doi:10.1136/bmj.327.7414.557.CrossRef

13.

Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.PubMed

14.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.PubMedCrossRef

15.

Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.PubMedCrossRef

16.

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clin Res). 1997;315(7109):629–34.CrossRef

17.

Camps C, Sarries C, Roig B, Sanchez JJ, Queralt C, Sancho E, et al. Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients. Clin Lung Cancer. 2003;4(4):237–41.PubMedCrossRef

18.

Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Anna Oncol Off J Eur Soc Med Oncol ESMO. 2004;15(8):1194–203. doi:10.1093/annonc/mdh319.CrossRef

19.

de las Penas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, Garcia-Carbonero R, et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2006;17(4):668–75. doi:10.1093/annonc/mdj135.CrossRef

20.

Vinolas N, Provencio M, Reguart N, Cardenal F, Alberola V, Sanchez-Torres JM, et al. Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer (Amst Neth). 2011;71(2):191–8. doi:10.1016/j.lungcan.2010.05.005.CrossRef

21.

Provencio M, Camps C, Cobo M, De las Penas R, Massuti B, Blanco R, et al. Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer. Cancer Chemother Pharmacol. 2012;70(6):883–90. doi:10.1007/s00280-012-1985-9.PubMedCrossRef

22.

Iranzo V, Sirera R, Bremnes RM, Blasco A, Jantus-Lewintre E, Taron M, et al. Chemotherapy-induced neutropenia does not correlate with DNA repair gene polymorphisms and treatment efficacy in advanced non-small-cell lung cancer patients. Clin Lung Cancer. 2011;12(4):224–30. doi:10.1016/j.cllc.2011.03.023.PubMedCrossRef

23.

Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, Nannizzi S, et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clinical Cancer Res Off J Am Assoc Cancer Res. 2008;14(6):1797–803. doi:10.1158/1078-0432.ccr-07-1364.CrossRef

24.

Ludovini V, Floriani I, Pistola L, Minotti V, Meacci M, Chiari R, et al. Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2011;6(12):2018–26. doi:10.1097/JTO.0b013e3182307e1f.

25.

Tiseo M, Bordi P, Bortesi B, Boni L, Boni C, Baldini E, et al. ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. Br J Cancer. 2013;108(8):1695–703. doi:10.1038/bjc.2013.127.PubMedPubMedCentralCrossRef

26.

Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res Off J Am Assoc Cancer Res. 2004;10(15):4939–43. doi:10.1158/1078-0432.ccr-04-0247.CrossRef

27.

Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22(13):2594–601. doi:10.1200/jco.2004.08.067.CrossRef

28.

Suk R, Gurubhagavatula S, Park S, Zhou W, Su L, Lynch TJ, et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res Off J Am Assoc Cancer Res. 2005;11(4):1534–8. doi:10.1158/1078-0432.ccr-04-1953.CrossRef

29.

Booton R, Ward T, Heighway J, Taylor P, Power F, Ashcroft L, et al. Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer. Cancer. 2006;106(11):2421–7. doi:10.1002/cncr.21885.PubMedCrossRef

30.

Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulias V, et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer. 2009;10(2):118–23. doi:10.3816/CLC.2009.n.015.PubMedCrossRef

31.

Krawczyk P, Wojas-Krawczyk K, Mlak R, Kucharczyk T, Biernacka B, Milanowski J. Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer—a pilot study. Folia Histochem Cytobiol Pol Acad Sci Pol Histochem Cytochem Soc. 2012;50(1):80–6. doi:10.2478/18700.CrossRef

32.

Joerger M, Burgers SA, Baas P, Smit EF, Haitjema TJ, Bard MP, et al. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer. 2012;118(9):2466–75. doi:10.1002/cncr.26562.PubMedCrossRef

33.

Ryu JS, Hong YC, Han HS, Lee JE, Kim S, Park YM, et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer (Amst Neth). 2004;44(3):311–6. doi:10.1016/j.lungcan.2003.11.019.CrossRef

34.

Shiraishi K, Kohno T, Tanai C, Goto Y, Kuchiba A, Yamamoto S, et al. Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(33):4945–52. doi:10.1200/jco.2010.30.5334.CrossRef

35.

Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(21):3540–6. doi:10.1200/jco.2008.20.8793.CrossRef

36.

Su D, Ma S, Liu P, Jiang Z, Lv W, Zhang Y, et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer (Amst Neth). 2007;56(2):281–8. doi:10.1016/j.lungcan.2006.12.002.CrossRef

37.

Yao CY, Huang XE, Li C, Shen HB, Shi MQ, Feng JF, et al. Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers. Asian Pac J Cancer Prev APJCP. 2009;10(5):859–64.

38.

Dong J, Hu Z, Shu Y, Pan S, Chen W, Wang Y, et al. Potentially functional polymorphisms in DNA repair genes and non-small-cell lung cancer survival: a pathway-based analysis. Mol Carcinog. 2012;51(7):546–52. doi:10.1002/mc.20819.PubMedCrossRef

39.

Hong W, Wang K, Zhang YP, Kou JY, Hong D, Su D, et al. Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population. J Zhejiang Univ Sci B. 2013;14(3):207–15. doi:10.1631/jzus.B1200101.PubMedCentralPubMedCrossRef

40.

KimCurran V, Zhou C, Schmid-Bindert G, Shengxiang R, Zhou S, Zhang L, et al. Lack of correlation between ERCC1 (C8092A) single nucleotide polymorphism and efficacy/toxicity of platinum based chemotherapy in Chinese patients with advanced non-small cell lung cancer. Adv Med Sci. 2011;56(1):30–8. doi:10.2478/v10039-011-0013-3.PubMedCrossRef

41.

Ren S, Zhou S, Wu F, Zhang L, Li X, Zhang J, et al. Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy. Lung Cancer (Amst Neth). 2012;75(1):102–9. doi:10.1016/j.lungcan.2011.05.023.CrossRef

42.

Liu L, Yuan P, Wu C, Zhang X, Wang F, Guo H, et al. Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer (Amst Neth). 2011;73(1):110–5. doi:10.1016/j.lungcan.2010.11.004.CrossRef

43.

Yuan P, Miao XP, Zhang XM, Wang ZH, Tan W, Zhang XR, et al. Correlation of genetic polymorphisms in nucleotide excision repair system to sensitivity of advanced non-small cell lung cancer patients to platinum-based chemotherapy. Ai zheng Aizheng Chin J Cancer. 2005;24(12):1510–3.

44.

Chen S, Huo X, Lin Y, Ban H, Li W, Zhang B, et al. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients. Int J Hyg Environ Health. 2010;213(2):140–5. doi:10.1016/j.ijheh.2010.01.004.PubMedCrossRef

45.

Li Y, Huang XE, Jin GF, Shen HB, Xu L. Lack of any relationship between chemotherapy toxicity in non-small cell lung cancer cases and polymorphisms in XRCC1 codon 399 or XPD codon 751. Asian Pac J Cancer Prev APJCP. 2011;12(3):739–42.

46.

Cheng H, Qin Q, Sun X, Li F, Sun N, Cheng L, et al. Predictive effect of XPA and XPD polymorphisms on survival of advanced NSCLC patients treated with platinum-based chemotherapy: a three-dimensional (3-D), polyacrylamide gel-based DNA microarray method. Technol Cancer Res Treat. 2013. doi:10.7785/tcrt.2012.500337.

47.

Wang J, Zhang Q, Zhang H, Wang Q, Yang X, Gu Y, et al. Association between polymorphisms of ERCC1 and response in patients with advanced non-small cell lung cancer receiving cisplatin-based chemotherapy. Zhongguo fei ai za zhi Chin J Lung Cancer. 2010;13(4):337–41.

48.

Wu W, Li H, Wang H, Zhao X, Gao Z, Qiao R, et al. Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients. PloS one. 2012;7(3):e33200. doi:10.1371/journal.pone.0033200.PubMedCentralPubMedCrossRef

49.

Wu W, Zhang W, Qiao R, Chen D, Wang H, Wang Y, et al. Association of XPD polymorphisms with severe toxicity in non-small cell lung cancer patients in a Chinese population. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15(11):3889–95. doi:10.1158/1078-0432.ccr-08-2715.CrossRef

50.

Zhang ZY, Tian X, Wu R, Liang Y, Jin XY. Predictive role of ERCC1 and XPD genetic polymorphisms in survival of Chinese non-small cell lung cancer patients receiving chemotherapy. Asian Pac J Cancer Prev APJCP. 2012;13(6):2583–6.CrossRef

51.

Cheng J, Ha M, Wang Y, Sun J, Chen J, Tong C. A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer. J Cancer Res Clin Oncol. 2012;138(2):231–8. doi:10.1007/s00432-011-1090-1.PubMedCrossRef

52.

Li XD, Han JC, Zhang YJ, Li HB, Wu XY. Common variations of DNA repair genes are associated with response to platinum-based chemotherapy in NSCLCs. Asian Pac J Cancer Prev APJCP. 2013;14(1):145–8.CrossRef

53.

Liao WY, Shih JY, Chang GC, Cheng YK, Yang JC, Chen YM, et al. Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2012;7(6):973–81. doi:10.1097/JTO.0b013e31824fe98c.

54.

Qian XP, Liu BR, Yan WY, Wang LF, Wei J, Xie L, et al. Single nucleotide polymorphism in ERCC1 C118T predicts the outcome of NSCLC patients receiving platinum-based chemotherapy. Mod Oncol. 2011;19(10):1997–2001.

55.

Xu CA, Li Q, Wang XJ, Li L. Sensitivity relationship of ERCC1 and XRCC1 genetic polymorphism on response of platinum-based chemotherapy in advanced NSCLC. J Prac Oncol. 2012;27(3):245–50.

56.

Han Y, Liang J, Lv HY, Yao RY, Jiang T, Zhou F, et al. ERCC1 and XRCC1 gene polymorphisms and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Chin J Prac Int Med. 2011;31(8):638–9.

57.

Ding ZH, Xu L, Gao CM, Wu JZ, Shi MQ, Feng JF. Polymorphisms in XPD751 gene and sensitivity to gemcitabine /cisplatin chemotherapy in advanced stage of non-small-cell lung cancer. Acta Univ Med Nanjing. 2008;28(4):457–61.

58.

Liu YF, Guan XX, Chen LB, Chen YT. Study on ERCC1, XPD and XPA polymorphisms for prediction of platinum-based chemotherapy sensitivity in non-small cell lung cancer. Chin J Cancer Prev Treat. 2008;15(17):1285–8.

59.

Liu XZ, Qian XP, Liu BR, Hu WJ, Wang LF, Wei J, et al. Singlenueleotide polymorphismsin in XRCC1, XPD and platinum prognosis in non-small-cell lung cancer patients. J Clin Med Prac. 2008;12(5):7–11.

60.

Wang SH, Jiang CF. The ERCC1 codon118 gene expression significance in predicting the three generations of platinum containing regimen in advanced non-small cell lung cancer. Chin J Clin Oncol Rehabil. 2012;19(5):388–90.

61.

Song DG, Liu J, Wang ZH, Song B, Li CZ. XRCC1 and XPD genetic polymorphisms predict clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer. Chin J Gerontol. 2007;27:1684–6.

62.

Fan H, Huang XE, Zhang Q, Gao LL, Xu L, Jin GF, et al. Relationship of XRCC1 and XPD gene polymorphisms with chemosensitivity to platinum-based chemotherapy in advanced non-small cell lung cancer. Pract Geriatr. 2008;22(4):306–14.

63.

Ren BH, Yang X, Li M, Jiang F, Yin R, Xu L. Single nucleotide polymorphisms in DNA repair ERCC1 predict clinical response to platinum-based chemotherapy in non-small cell lung cancer. Chin J Exp Surg. 2010;27(9):1200–2.

64.

Park SY, Hong YC, Kim JH, Kwak SM, Cho JH, Lee HL, et al. Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients. Med Oncol (Northwood Lond Engl). 2006;23(4):489–98. doi:10.1385/mo:23:4:489.CrossRef

65.

Han JY, Yoon KA, Park JH, Lee YJ, Lee GK, Han JH, et al. DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma. Cancer. 2011;117(14):3201–8. doi:10.1002/cncr.25863.PubMedCrossRef

66.

Okuda K, Sasaki H, Hikosaka Y, Kawano O, Yukiue H, Yano M, et al. Excision repair cross complementation group 1 polymorphisms predict overall survival after platinum-based chemotherapy for completely resected non-small-cell lung cancer. J Surg Res. 2011;168(2):206–12. doi:10.1016/j.jss.2009.09.006.PubMedCrossRef

67.

Li D, Zhou Q, Liu Y, Yang Y, Li Q. DNA repair gene polymorphism associated with sensitivity of lung cancer to therapy. Med Oncol (Northwood, London, England). 2012;29(3):1622–8. doi:10.1007/s12032-011-0033-7.CrossRef

68.

Mathiaux J, Le Morvan V, Pulido M, Jougon J, Begueret H, Robert J. Role of DNA repair gene polymorphisms in the efficiency of platinum-based adjuvant chemotherapy for non-small cell lung cancer. Mol Diagn Ther. 2011;15(3):159–66. doi:10.2165/11591140-000000000-00000.PubMedCrossRef

69.

Butkiewicz D, Drosik A, Suwinski R, Krzesniak M, Rusin M, Kosarewicz A, et al. Influence of DNA repair gene polymorphisms on prognosis in inoperable non-small cell lung cancer patients treated with radiotherapy and platinum-based chemotherapy. Int J Cancer J Int Cancer. 2012;131(7):E1100–8. doi:10.1002/ijc.27596.CrossRef

70.

Hua ZH, Fang WZ, Zhao ZQ, Xie FW, Ou-yang XN, Song HT. Association study of ERCC1 and ERCC4 genetic polymorphism with response and survival in non-small cell lung cancer patients treated with cisplatin-based chemotherapy. Chin J Clin Pharmacol Ther. 2011;16(7):772–8.

71.

Wei SZ, Zhan P, Shi MQ, Shi Y, Qian Q, Yu LK, et al. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med Oncol (Northwood, London, England). 2011;28(1):315–21. doi:10.1007/s12032-010-9443-1.CrossRef

72.

Wei HB, Lu XS, Shang LH, Xu G, Hu J, Che DH, et al. Polymorphisms of ERCC1 C118T/C8092A and MDR1 C3435T predict outcome of platinum-based chemotherapies in advanced non-small cell lung cancer: a meta-analysis. Arch Med Res. 2011;42(5):412–20. doi:10.1016/j.arcmed.2011.07.008.PubMed

73.

Yu D, Shi J, Sun T, Du X, Liu L, Zhang X, et al. Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients. Tumour Biol J Int Soc Oncodevelop Biol Med. 2012;33(3):877–84. doi:10.1007/s13277-011-0314-y.CrossRef

74.

Yin M, Yan J, Voutsina A, Tibaldi C, Christiani DC, Heist RS, et al. No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. Lung Cancer (Amst Neth). 2011;72(3):370–7. doi:10.1016/j.lungcan.2010.10.011.CrossRef

75.

Xu TP, Shen H, Liu LX, Shu YQ. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports. Gene. 2013. doi:10.1016/j.gene.2013.05.021.PubMedCentral

76.

Zhou C, Ren S, Zhou S, Zhang L, Su C, Zhang Z, et al. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients. Jap J Clin Oncol. 2010;40(10):954–60. doi:10.1093/jjco/hyq071.CrossRef

Title: The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis
Authors: Yanlong Yang
Lei Xian
Publication date: 01-04-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 4/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-1493-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2014

BTG1 expression correlates with the pathogenesis and progression of breast carcinomas

The prognostic value of Smad4 mRNA in patients with prostate cancer

Overexpression of miR-145 increases the sensitivity of vemurafenib in drug-resistant colo205 cell line

Absent expression of FLNA is correlated with poor prognosis of nasopharyngeal cancer

Strong claudin 5 expression is a poor prognostic sign in pancreatic adenocarcinoma

The MMP-1, MMP-2, and MMP-9 gene polymorphisms and susceptibility to bladder cancer: a meta-analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer